Abstracts tagged "psoriatic arthritis and patient-reported outcome measures"

Abstract Number: 423 • 2019 ACR/ARP Annual Meeting
Patient Reported Outcomes over 2 Years in Psoriatic Arthritis Patients Initiating Treatment with 1st, 2nd or 3rd TNF Inhibitor in Routine Care – Was PRO Remission Achieved? Results from the EuroSpA Collaboration
Lykke Midtbøll Ørnbjerg¹, Lennart Jacobsson ², Anne Gitte Loft ³, Florenzo Iannone ⁴, Michael J. Nissen ⁵, Eirik Kristianslund ⁶, Herman Mann ⁷, Maria José Santos ⁸, Manuel Pombo-Suarez ⁹, Kari K. Eklund ¹⁰, Ziga Rotar ¹¹, Bjorn Gudbjornsson ¹², Mehmet Akif Öztürk ¹³, Catalin Codreanu ¹⁴, Marleen van de Sande ¹⁵, Johan Wallman ¹⁶, Ennio Giulio Favalli ¹⁷, Burkhard Moeller ¹⁸, Joe Sexton ¹⁹, Karel Pavelka ⁷, Elsa Vieira-Sousa ²⁰, Carlos Sánchez-Piedra ²¹, Nina Trokovic ²², Matija Tomsic ²³, Thorvardur J Love ²⁴, Ayşe Cefle ²⁵, Ruxandra IONESCU ²⁶, Irene van der Horst-Bruinsma ¹⁵, Gareth Jones ²⁷, Cecilie Heegaard Brahe ²⁸, Merete Lund Hetland ¹ and Mikkel Østergaard ²⁹, ¹DANBIO and Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre of Head and Orthopaedics, Rigshospitalet, Copenhagen, Denmark, ²Dept of Rheumatology and Inflammation Research, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Sweden,, Gothenburg, Sweden, ³Department of Rheumatology, Aarhus University Hospital., Aarhus, Denmark, ⁴Department of Emergency and Transplantation , Rheumatology Unit, University Hospital of Bari, Bari, Italy., Bari, Italy, ⁵University Hospital Geneva, Geneva, Switzerland, ⁶Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway., Oslo, Norway, ⁷Institute of Rheumatology, Department of Rheumatology, 1st Faculty of Medicine, Prague, Czech Republic, Prague 2, Czech Republic, ⁸Rheumatology department, Hospital Garcia de Orta, Almada, Portugal, ⁹Unit Research, Spanish Society of Rheumatology, Madrid, Spain, ¹⁰ROB-FIN registry, Department of Medicine, Helsinki University and University Hospital, Helsinki, Finland, ¹¹UMC LJUBLJANA, DPT. OF RHEUMATOLOGY, LJUBLJANA, Slovenia, ¹²Centre for Rheumatology Research, Landspitali and Faculty of Medicine, University of Iceland, Reykjavik, Iceland, ¹³Division of Rheumatology, Gazi University School of Medicine, Ankara, Turkey, Ankara, Turkey, ¹⁴Center of Rheumatic Diseases, University of Medicine and Pharmacy, Bucharest, Romania., Bucharest, Romania, ¹⁵Amsterdam University Medical Center, Amsterdam, Netherlands, ¹⁶Department of Clinical Sciences Lund, Rheumatology Lund University, Lund, Sweden, ¹⁷University of Milan, Department of Rheumatology, ASST Gaetano Pini-CTO, Milan, Lombardia, Italy, ¹⁸University Hospital Bern, Bern, Switzerland, ¹⁹Diakonhjemmet Hospital, Dept. of Rheumatology, Oslo, Norway, ²⁰Rheumatology and Metabolic Bone Diseases, Hospital de Santa Maria - Centro Hospitalar Lisboa Norte, EPE | Rheumatology Research Unit, Instituto de Medicina Molecular - Faculty of Medicine, University of Lisbon, Lisbon Academic Medical Centre, Lisbon, Portugal,, Lisbon, Portugal, ²¹Research Unit, Spanish Society of Rheumatology, Madrid, Spain, ²²Helsinki University Central Hospital, Helsinki, Finland, ²³Department of Rheumatology, University Medical Centre, Ljubjana, Slovenia, ²⁴Faculty of Medicine, University of Iceland, Reykjavik, Iceland, ²⁵Division of Rheumatology, Kocaeli University School of Medicine, Kocaeli, Turkey, Kocaeli, Turkey, ²⁶SPITALUL CLINIC SFANTA MARIA, Bucharest, ²⁷University of Aberdeen, Aberdeen, United Kingdom, ²⁸Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet Glostrup, Denmark, Copenhagen, Denmark, ²⁹Copenhagen Center for Arthritis Research, University of Copenhagen, Copenhagen, Denmark
Background/Purpose: Patient Reported Outcomes (PROs) provide important information on assessment of pain, disease activity, fatigue and physical function in patients with psoriatic arthritis (PsA). Knowledge…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].